A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs V-930 (Primary)
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Acronyms FIM
- 10 Feb 2015 Biomarkers information updated
- 12 Nov 2008 Actual patient number identified as 26 from ClinicalTrials.gov.
- 12 Nov 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.